Will CRISPR Therapeutics AG (CRSP) stock rise or fall over the next month?
Out of 197 instances in the last 4 years that CRISPR Therapeutics AG stock saw a 5-day decline of 7.3% or more, 112 of them resulted in CRSP stock rising over the subsequent one month period (21 trading days). This historical pattern reflects 112 out of 197, or about 59% chance of gain in CRSP stock over the coming month.
What are analysts'price targets for CRISPR Therapeutics'stock?
18 analysts have issued 12 month price targets for CRISPR Therapeutics' stock. Their forecasts range from $110.00 to $210.00. On average, they expect CRISPR Therapeutics' stock price to reach $158.80 in the next year. This suggests a possible upside of 34.0% from the stock's current price.
What is CRISPR Therapeutics'return on equity?
CRISPR Therapeutics had a trailing twelve-month return on equity of 19.19% and a net margin of 45.64%. View CRISPR Therapeutics' earnings history.
Will CRISPR Therapeutics'stock outperform the S&P 500?
MarketBeat's community ratings are surveys of what our community members think about CRISPR Therapeutics and other stocks. Vote “Outperform” if you believe CRSP will outperform the S&P 500 over the long term.
Why did Crispr stock go down?
CRISPR Therapeutics (CRSP 7.57%) stock sank by 15.9% in January, according to data from S&P Global Market Intelligence, amid a surge of bearish momentum impacting the broader market. An assortment of risk factors last month led investors to sell stocks lower.
Is Crispr stock a good buy now?
CRISPR Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.63, and is based on 10 buy ratings, 6 hold ratings, and no sell ratings.
Should I hold Crispr stock?
Out of 14 analysts, 4 (28.57%) are recommending CRSP as a Strong Buy, 5 (35.71%) are recommending CRSP as a Buy, 5 (35.71%) are recommending CRSP as a Hold, 0 (0%) are recommending CRSP as a Sell, and 0 (0%) are recommending CRSP as a Strong Sell.
Will CRSP stock go up?
Stock Price Forecast The 22 analysts offering 12-month price forecasts for CRISPR Therapeutics AG have a median target of 108.50, with a high estimate of 220.00 and a low estimate of 46.00. The median estimate represents a +43.10% increase from the last price of 75.82.
Is CRISPR a good investment 2021?
Shares of CRISPR Therapeutics (CRSP 0.90%) sank 50.5% in 2021, according to data from S&P Global Market Intelligence. After surging roughly 151% across 2020's trading, investors reassessed the gene-editing specialist's drug pipeline and moved out of the company's stock.
What will CRSP stock be worth in 2025?
CRISPR Technologies: 191,416% implied sales growth by 2025 CRISPR Therapeutics (CRSP -5.17%), a company leaning on gene-editing technology to precisely alter genomic DNA and tackle hard-to-treat diseases, is expected to see sales climb from $719,000 in 2020 to a consensus of $1.377 billion by 2025.
What is the best CRISPR stock to buy?
5 best CRISPR stocks to buyCompanyMarket CapCRISPR Therapeutics (NASDAQ:CRSP)$6.1 billionEditas Medicine (NASDAQ:EDIT)$1.9 billionIntellia Therapeutics (NASDAQ:NTLA)$8.9 billionVerve Therapeutics (NASDAQ:VERV)$1.9 billion1 more row
What's going on with CRISPR stock?
Crispr Therapeutics Stock Shows Rising Price Performance With Jump To 94 RS Rating. Crispr Therapeutics stock saw a positive improvement to its Relative Strength (RS) Rating on Friday, rising from 90 to 94.
Is CRISPR undervalued?
Valuation metrics show that CRISPR Therapeutics AG may be overvalued. Its Value Score of D indicates it would be a bad pick for value investors.
Who owns Crispr stock?
Top 10 Owners of CRISPR Therapeutics AGStockholderStakeShares ownedBlackRock Fund Advisors2.53%1,962,052Loomis, Sayles & Co. LP1.67%1,290,905Fidelity Management & Research Co...1.63%1,261,622The Vanguard Group, Inc.1.51%1,170,3366 more rows
What is the best CRISPR stock to buy?
5 best CRISPR stocks to buyCompanyMarket CapCRISPR Therapeutics (NASDAQ:CRSP)$6.1 billionEditas Medicine (NASDAQ:EDIT)$1.9 billionIntellia Therapeutics (NASDAQ:NTLA)$8.9 billionVerve Therapeutics (NASDAQ:VERV)$1.9 billion1 more row
Should I buy CRISPR stock Zacks?
The Earnings Yield (also known as the E/P ratio) measures the anticipated yield (or return) an investment in a stock could give you based on the earnings and the price paid....Momentum Scorecard. More Info.Zacks RankDefinitionAnnualized Return1Strong Buy24.75%2Buy18.15%3Hold9.70%4Sell5.35%2 more rows
Is CRISPR stock a buy Zacks?
CRISPR Therapeutics AG is holding a Zacks Rank of #3 (Hold) right now. The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 78, which puts it in the top 31% of all 250+ industries.
Is CRISPR undervalued?
At a high level, most CRISPR stocks are wildly overvalued given their level of maturity. Unlike software companies, it's very difficult for a drug developer to reach a market valuation of $10 billion.
CRISPR Therapeutics AG (CRSP) Reports Q4 Loss, Tops Revenue Estimates
Mario Gabelli is Selling These 10 Stocks
CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of -5.75% and 139.40%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
2 Exciting Trends That Could Shape Healthcare's Future
In this article, we discuss the 10 stocks that Mario Gabelli is selling. If you want to skip our detailed analysis of Gabelli’s history, investment philosophy, and hedge fund performance, go directly to Mario Gabelli is Selling These 5 Stocks. Mario Gabelli is an Italian-American investor and hedge fund manager who founded GAMCO Investors in […]
CRISPR Therapeutics to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
Healthcare companies are at work on potentially groundbreaking therapies in trending areas that are being overlooked by many investors. In this segment from "This Week in Healthcare," recorded on Jan.
Analysts Estimate CRISPR Therapeutics AG (CRSP) to Report a Decline in Earnings: What to Look Out for
ZUG, Switzerland and CAMBRIDGE, Mass., Feb.
CRISPR (CRSP) to Report Q4 Earnings: What's in the Cards?
CRISPR Therapeutics AG (CRSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What is the P/E ratio of CRISPR?
On CRISPR Therapeutics' (CRSP) Q4 earnings call, investor focus is likely to be on updates on the progress of the company's pipeline candidates, especially its lead candidate CTX001.
What is CRISPR Therapeutics?
The P/E ratio of CRISPR Therapeutics is 16.82 , which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 15.69.
What is the CRISPR Therapeutics mailing address?
CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.
What is the CRSP symbol?
CRISPR Therapeutics' mailing address is BAARERSTRASSE 14, ZUG V8, CH-6300. The company can be reached via phone at (141) 561-3277 or via email at [email protected].
Does CRISPR pay dividends?
CRISPR Therapeutics trades on the NASDAQ under the ticker symbol "CRSP."
What is CRISPR therapeutics?
CRISPR Therapeutics does not currently pay a dividend.
Where is CRISPR headquartered?
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA. It has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company’s lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient’s hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19 positive malignancies; allogeneic CAR-T programs comprising CTX120 targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130 for the treatment of solid tumors and hematologic malignancies. It develops regenerative medicine programs in diabetes; and in vivo and other genetic disease programs to treat glycogen storage disease Ia, Duchenne muscular dystrophy, myotonic dystrophy type 1, and cystic fibrosis. The company has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. The company was formerly known as Inception Genomics AG and changed its name to CRISPR Therapeutics AG in April 2014. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
What was the CRISPR 3rd quarter loss?
CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland. More... Sector.
When was CRISPR phase 1 results released?
CRISPR published its third-quarter results on Nov. 3. The company posted a loss of $1.67 per share on sales of $0.82 million, while the average analyst estimate had called for a loss of $1.75 per share on $1.3 million.
What happens if you buy CRISPR stock?
CRISPR published phase 1 trial results for CTX110 on on Oct. 12. CTX110 is the company's chimeric antigen receptor T-cell (CAR-T) therapy for large B-cell lymphomas. As a clinical-stage biotech, it's not unusual for CRISPR stock to post substantial swings after new trial data is released, and the market was broadly unimpressed by the gene-editing specialist's latest update.
Does patience pay for most stocks?
Answer: If you buy and hold CRISPR stock, the expectation is over time the near-term fluctuations will cancel out, and the long-term positive trend will favor you – at least if the company is otherwise strong.
Is the average return after a rise lower than after a fall?
Overall, according to data and Trefis machine learning engine’s calculations, patience absolutely pays for most stocks!
